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Ca2+ concentrationSigma-1 receptors are highly expressed in the brain. The downstream signaling mechanisms associated with
the sigma-1 receptor activation have been shown to involve the activation of protein kinase C (PKC), the
control of Ca2 homoeostasis and the regulation of voltage- and ligand-gated ion channels. But few studies
examined the regulatory effect of sigma-1 receptors on metabotropic receptor signaling. The present paper
studied the regulatory effect of sigma-1 receptors on the signaling of dopamine D1 receptors, one of
metabotropic receptors, by examining the effect of sigma-1 receptor agonists on the D1 receptor agonist-
induced cAMP-dependent protein kinase (PKA) activation at presynaptic sites using the synaptosomes from
the prelimbic cortex. The results showed that sigma-1 receptor agonists alone had no effects on the PKA
activity, but could amplify the D1 receptor agonist-induced PKA activation. The sigma-1 receptor agonist also
ampliﬁed the membrane-permeable analog of cAMP- and the adenylyl cyclase (AC) activator-induced PKA
activation, but did not on the D1 receptor agonist-induced AC activation. The conventional PKC (cPKC),
especially the PKCβI, and the extracellular Ca2+ inﬂux through L-type Ca2+ channels might play key roles in
the amplifying effect of the sigma-1 receptor agonists. The activation of PKC by sigma-1 receptor agonists
was the upstream event of the increase in the intrasynaptosomal Ca2+ concentration. These results suggest
that sigma-1 receptors may amplify the D1 receptor agonist-induced PKA activation by sigma-1 receptors -
cPKC (especially the PKCβI) - L-type Ca2+ channels - Ca2+ - AC and/or cAMP signaling pathway.Medical Neurobiology, Fudan
ad, Shanghai, 200032, People's
64174579.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Sigma receptors, recognized as unique receptors, are widely
distributed in the mammalian brain. Sigma receptors have been
known to be implicated in numerous physiological and pathophys-
iological processes such as learning andmemory, schizophrenia, drug-
seeking behaviors and psychostimulant-induced behavioral sensiti-
zation [1]. However, many important questions involving the
downstream signaling pathways of sigma receptors remain to be
studied.
Sigma receptors contain two subtypes, sigma-1 and sigma-2
receptors. The sigma-1 receptor has been cloned and its predicted
amino acid sequence suggests two transmembrane domains, demon-
strating that it does not correspond to a traditional G-protein-coupled
receptor [2]. One of the earliest questions about the downstream
signaling mechanisms associated with sigma-1 receptor activation
involved their possible coupling to G-proteins [3]. This issue has been
studied with different experimental approaches, but the results arecontradictory. Some sigma-1 agonists seemed to act through G-
proteins, whereas others did not [4,5]. Although the coupling of
sigma-1 receptors to G-proteins remains controversial, the down-
stream signaling mechanisms of the sigma-1 receptors have been
shown to involve the activation of protein kinase C (PKC), the control
of Ca2 homoeostasis and the regulation of voltage- and ligand-gated
ion channels such as Ca2+ channels, transient outward K+ channels,
Ca2+-dependent K+ channels and NMDA-gated ion channels [6–8]. In
addition, studies by Hayashi and Su et al showed that the sigma-1
receptors could exist on lipid rafts at the endoplasmic reticulum (ER)
membrane and modulate intracellular Ca2+ mobilization at the ER
when translocated from lipid droplets on the ER after stimulated by
agonists [3,9].
In our previous study, when we examined the mechanism of the
effect of neurosteroid dehydroepiandrosterone sulphate (DHEAS) on
presynaptic glutamate release in the prelimbic cortex, we found that
the sigma-1 receptor antagonist partially blocked the effect of DHEAS,
but the dopamine D1 receptor antagonist completely blocked the
effect of DHEAS [10]. This result suggests that it is through D1
receptors that sigma-1 receptors produce the promoting effect on
glutamate release because D1 receptor antagonist can completely
block this effect. In addition, some behavioral evidence suggested that
sigma-1 receptors might induce behavioral changes via their actions
on D1 receptor [11]. However, the direct evidence supporting that
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the present paper, we studied the regulatory effect of sigma-1
receptors on the signaling of dopamine D1 receptors by examining the
effect of sigma-1 receptor agonists on the D1 receptor agonist-
induced cAMP-dependent protein kinase (PKA) activation at presyn-
aptic sites using the synaptosomes from the prelimbic cortex. In
addition, since considerable morphological and functional evidence
have shown that synaptosomes are sealed particles that contain
vesicles, viable mitochondria and all the components necessary to
store, release and retain neurotransmitters [12], we also further
investigate the mechanism underlying the amplifying effect of sigma-
1 receptor agonists on the D1 receptor agonist-induced PKA activation
using pharmacological approaches combined with the measure of the
intrasynaptosomal Ca2+ concentration.
2. Materials and methods
2.1. Synaptosome preparation
Male Sprague-Dawley rats (200-240 g) were anesthetized with
chloral hydrate (400 mg/kg, i.p.). All experimental procedures
conformed to Fudan University as well as international guidelines
on the ethical use of animals and all efforts were made to minimize
the number of animals used and their suffering. Synaptosomes were
prepared as described previously [13]. The prelimbic cortex was
dissected and homogenized in 0.32 M sucrose solution at 4 °C using
the Art-Miccra D-8 tissue grinder with a motor-driven pestle rotating
at 900 rpm. The homogenate was centrifuged at 3000×g for 3 min at
4 °C. The supernatant (S1) was centrifuged at 14500×g for 12 min at
4 °C. The pellet (P2) was resuspended and loaded onto Percoll
gradients consisting three steps of 23, 10 and 3% Percoll in 0.32 M
sucrose additionally containing 1 mM EDTA and 250 μM DTT. The
gradients were centrifuged at 32500×g for 6.5 min at 4 °C. Synapto-
somes were harvested from the interface between the 23 and 10%
Percoll layers and washed in Hanks' balanced salt solution (HBSS)
containing 140 mM NaCl, 5 mM KCl, 5 mM NaHCO3, 1 mM MgCl2,
1.2 mM Na2HPO4, 10 mM glucose and 20 mM HEPES, pH 7.4. Washed
synaptosomes were centrifuged at 27000×g for 15 min at 4 °C. The
protein concentration of the synaptosomes was determined by the
method of Lowry et.al [14] with the bovine serum albumin as the
standard protein.
2.2. Assessment of PKA activity
The activity of PKA was assessed with the PepTag Non-Radioactive
PKA Assay Kits from Promega. The assay was based on the change in
the net charge of the ﬂuorescent PKA substrate before and after
phosphorylation. This change in the net charge of the substrate
allowed the phosphorylated and nonphosphorylated version of the
substrate to be rapidly separated on an agarose gel at neutral pH. The
PKA activity was quantiﬁed based on the intensity of the ﬂuorescence
of the phosphorylated peptide and no internal standardwas used [15].
2.3. Assessment of AC activity
The assessment of AC activity was performed using cAMP-Glo
Assay (Promega) following the protocol of the manufacturer [16].
Brieﬂy, the synaptosomes in each well of the assay plate were treated
with 1X phosphate-buffered saline (PBS) containing phosphodiester-
ase inhibitors IBMX and Ro20-1724 to prevent the degradation of
cAMP. Accumulation of cAMP is used as an index of the AC activity.
The cAMP is detected using the detection solution provided in the kit
after cell lysis. The luminescence was measured using a MDS
SpectraMax L (Molecular Devices Corporation). A standard curve
was performed in parallel for each experiment using serial dilutions of
cAMP provided with the kit.2.4. Western blotting
Immunoblot analysis of sigma-1 receptors was performed on
synaptosomes. The synaptosomal pellets were dissolved with
2×Laemmli sample buffer (100 mM Tris-HCl, 20% glycerol, 4% SDS,
pH 6.8) at 4 °C for 10 min [17]. The lysate was centrifuged at
12,000 rpm for 10 min at 4 °C [18]. Protein concentrations were
determined using a BCA kit (Pierce Chemicals, Rockford, IL). The
samples were treated with the SDS sample buffer at 95 °C for 5 min,
loaded on a 10% SDS polyacrylamide gel and blotted to a PVDF
membrane. Each blot was incubated with a normal rabbit IgG (1:200,
Invitrogen) or a rabbit anti-sigma-1 receptor antibody (1:200,
Invitrogen; 1:500, from Hayashi and Su) or a monoclonal anti-α-
tubulin antibody (1:4000, Santa Cruz Biotechnology). The horseradish
peroxidase development system as previously described [19] was
used for immunodetection. The immunoreactivity of the sigma-1
receptors was normalized to that of α-tubulin. Each experiment was
repeated at least ﬁve times.
Immunoblot analysis of cPKCβI was performed on cytosolic and
membrane fractions of synaptosomes prepared according to methods
described previously [20,21]. Brieﬂy, synaptosomal pellets were
transferred immediately to ice-cold homogenization buffer (20 mM
Tris-HCl, pH 7.5, 2 mM EDTA, 2 mM EGTA, 2 mM DTT, 50 μg/ml
aprotinin, 48 μg/ml leupeptin, 5 μMpepstatin A, 1 mMphenylmethyl-
sulfonyl ﬂuoride, 0.1 mM sodium vanadate, and 50 mMNaF) and then
lysed by sonication and centrifuged at 100,000×g for 1 h. The
supernatant was designated to the cytosolic fraction. The pellets
were incubated on ice for 10 min in homogenization buffer containing
0.3% Triton X-100 followed by centrifugation at 100,000×g for 30 min
to obtain the supernatant called the membrane fraction. Protein
concentrations were determined using a Bradford assay kit (Bio-Rad
Laboratories; Hercules, USA). Equal amounts (30 μg) of protein from
different experimental groups were loaded on a 8% SDS polyacryl-
amide gel, and blotted to a PVDF membrane, incubated with Rabbit
polyclonal cPKCβI antibody (1:1000; Abcam, Cambridge, UK). In order
to normalize for protein loading, we used a β-actin antibody (1:4000;
Santa Cruz Biotechnology, Inc., Santa Cruz, Bergheimer, Germany).
The proportion of membrane-bound cPKCβI was expressed as the
amount in membranes (Amembrane) relative to the total cellular
amount, according to Amembrane/(Amembrane+Acytosol).
2.5. Measurement of the intrasynaptosomal Ca2+ concentration
Puriﬁed synaptosomes were loaded with the acetoxymethyl ester
derivative of the calcium-sensitive ﬂuorescent dye Fluo-3 AM
(5.0 μM) for 30 min at 37 °C [22]. After being washed by centrifuga-
tion, the synaptosomes were resuspended in HBSS containing 1.0 mM
Ca2+ and 0.5 mMMg2+. Aliquotes (200 μl) of synaptosomal samples
were put into the 96 well plates with a ﬁnal protein concentration
200-250 μg/ml. The ﬂuorescence intensity was measured at 527 nm
in response to 485 nm excitation with Thermo Scientiﬁc Fluoroskan
Ascent equipped with ﬂuorescent analysis system. The Ca2+ concen-
tration is expressed as the ﬂuorescence ratiometric ΔF/F0%, which
reﬂects a relative, not an absolute, measurement of the free Ca2+
concentration [23]. ΔF/F0%=(F-F0)/F0×100, where F is the ﬂuores-
cence intensity at each time point and F0 is the ﬂuorescence intensity
of the “rest” level given by the average of ﬂuorescence intensities
before adding different reagent.
2.6. Drugs
Ethyleneglycol-bis(β-aminoethyl ether) N,N,N',N'- tetraacetic acid
(EGTA), 2-(4-morpholinoethyl-1)-phenylcyclohexane-1-carboxylate
hydrochloride (PRE084), verapamil hydrochloride, nimodipine, cheler-
ythrine, N-[2-(p-bromocinnamylamino)-ethyl]-5-isoquinolinesulfona-
mide dihydrochloride (H89), phorbol 12,13-dibutyrate (PDBu), AC915,
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diol hydrobromide (SKF38393),α-(4-ﬂuorophenyl)-4-(S-ﬂuoro-2-pyr-
imidinyl)-1-piperazinebutanol (BMY14802), cadmium chloride, rottle-
rin, 8-(4-chlorophenylthio)-adenosine-3',5'-cyclic monophosphate
(CPT-cAMP), 3-isobutyl-1-methylxanthine (IBMX), 4-(3-butoxy-4-
methoxybenzyl) imidazoline-2-one (Ro20-1724) and ω-conotoxin
GVIA were purchased from Sigma. (+)-N-allylnormetazocine
(SKF10047), thapsigargin, dizocilpine (MK801) and 5,6-bis[(4-ﬂuor-
ophenyl)amino]-1H-isoindole-1,3(2H)-dione (CGP53353) were from
Tocris Bioscience. ω-Agatoxin IVA was from Alomone. Fluo-3 AM and
pluronic F-127 were purchased from Molecular Probes. Non-radioac-
tive PKA Assay Kit, non-radioactive AC assay Kit and non-radioactive
PKC assay Kit were from Promega Corporation. Percoll was purchased
from Amersham Biosciences Corporation. cPKCβI antibody was from
Abcam. β-actin antibody was from Santa Cruz Biotechnology. Com-
mercial sigma-1 antibody was from Invitrogen. The self-made sigma-1
receptor antibody was from Dr. Teruo Hayashi's lab. Other reagents in
AR grades were products of Shanghai Chemical Plant. PRE084, EGTA,
verapamil, H89, SKF10047, ω-Agatoxin IVA, ω-conotoxin GVIA,
cadmium chloride, rottlerin, CPT-cAMP, SKF38393, BMY14802 and
MK-801 were dissolved in ddH2O and others were dissolved in DMSO.
When DMSO was used as the vehicle, drugs were initially dissolved in
100% DMSO and then diluted into HBSS at a ﬁnal DMSO concentration
of 0.1%, which, we conﬁrmed, had no detectable effects on the
parameters we observed.
2.7. Off-line data analysis
Numerical data were expressed as mean±SEM (standard error of
means). Statistical signiﬁcancewas determined using Student's paired
t-test for comparisons between two groups or ANOVA followed by
Student–Newman–Keuls test for comparisons among three or more
groups. In all cases n refers to the number of samples (different
samples come from different animals) studied.
3. Results
3.1. Sigma-1 receptor agonists alone have no effects on PKA activity, but
they can amplify the D1 receptor agonist-induced PKA activation
As shown in the left panel of Fig. 1A, the sigma-1 receptor agonist
PRE084 [24] alone had no effects on the PKA activity (n=5, PN0.05),
but it could signiﬁcantly increase the effect of the D1 receptor agonist
SKF38393 on the PKA activity in the synaptosomes from the prelimbic
cortex. The PKA activity was increased by 30.5±7.3% (n=5, Pb0.05)
at 4 min after SKF38393 (10 μM) alone, but after the synaptosomes
were pretreated with PRE084 (10 μM) for 2 min, the PKA activity
induced by SKF38393 was increased by 60.6±10.3% (n=5, Pb0.05,
compared to the SKF38393 alone group). We also observed the
inﬂuence of another sigma-1 receptor agonist SKF10047 [25] on the
effect of SKF38393. In the SKF38393 alone group, SKF38393 was
applied at 4 min before the measurement of PKA activity. In the
SKF10047+SKF38393 group, the synaptosomes were pretreated
with SKF10047 for 2 min before SKF38393 and then SKF38393 was
applied at 4 min before the measurement of PKA activity. The result
showed that SKF10047 alone had no effects on the PKA activity (n=4,
PN0.05, the right panel of Fig. 1B), but they could potentiate the effect
of SKF38393 on the PKA activity (n=4, the right panel of Fig. 1B). The
PKA activity was enhanced by 19.1±2.9% (n=4, Pb0.05) by
SKF38393 (10 μM) alone, but in the presence of SKF10047, the PKA
activity induced by SKF38393 (10 μM) was increased by 58.6±18.2%
(n=4, Pb0.05, compared to the SKF38393 alone group). Moreover,
the potentiating effect of PRE084 on the effect of SKF38393 could be
abolished by the sigma-1 receptor antagonist BMY14802 [26] (Fig. 1C,
n=4). In addition, we examined the expression of the sigma-1
receptors in the synaptosomes from the prelimbic cortex. The resultshowed that the sigma-1 receptors were detected in the synapto-
somes from the prelimbic cortex as a 25-kDa band inWestern blotting
(Fig. 1D). The commercial sigma-1 receptor antibody and the self-
made sigma-1 receptor antibody from Dr. Teruo Hayashi showed a
similar result. We also examined the expression of the sigma-1
receptors in the kidney tissues (Fig. 1D) as a control and obtained a
similar result to that reported by Hayashi and Su [27]. Meanwhile, the
synaptosomes incubatedwith the normal rabbit IgG showed no bands
(Fig. 1D).
To explore the possible sites of the action of the sigma-1 receptor
agonist in the D1-PKA signal transduction pathway, we observed the
inﬂuence of the sigma-1 receptor agonist on the effect of the
membrane-permeable analog of cAMP (CPT-cAMP) on the PKA ac-
tivity. As shown in Fig. 2A, the PKA activity was enhanced by 75.0±
12.2% (n=4, Pb0.05) by CPT-cAMP (1 μM) alone, but in the presence
of PRE084 (10 μM), the PKA activity after CPT-cAMP was increased by
162.0±16.1% (n=4, Pb0.05, compared to the CPT-cAMP alone
group). Also, the sigma-1 receptor agonist PRE084 could potentiate
the effect of the adenylyl cyclase (AC) activator forskolin on the PKA
activity (Fig. 2B). The PKA activity was enhanced by 36.1±7.8%
(n=4, Pb0.05) by forskolin (20 μM) alone, but in the presence of
PRE084 (10 μM), the PKA activity was increased by 64.8±9.7% (n=4,
Pb0.05, compared to the forskolin alone group). However, PRE084
did not have the potentiating effect on the D1 receptor agonist
SKF38393-induced AC activation (Fig. 2C). The AC activity was
enhanced by 19.3±4.7% (n=8, Pb0.05) by SKF38393 (10 μM)
alone and the AC activity was still increased by 18.8±2.9% by
SKF38393 (10 μM) in the presence of PRE084 (10 μM) (n=8, Pb0.05,
compared to control; PN0.05, compared to SKF38393 group).
3.2. PKC plays an important role in the amplifying effect of the sigma-1
receptor agonist on the D1 receptor agonist-induced PKA activation
To test the role of PKC in the amplifying effect of the sigma-1
receptor agonist on the D1 receptor agonist-induced PKA activation,
we observed the inﬂuence of the wide-spectrum PKC inhibitor
chelerythrine [28] on the amplifying effect of the sigma-1 receptor
agonist. The result showed that chelerythrine alone had no effects
(n=4), but the amplifying effect of PRE084 on the SKF38393-evoked
PKA activation disappeared in the presence of chelerythrine (Fig. 3A,
n=5). This result suggests that the activation of PKC by PRE084 may
play an important role in the amplifying effect of the sigma-1 receptor
agonist on the D1 receptor agonist-induced PKA activation. This
statement is further supported by our result that the PKC activator
PDBu can mimick the amplifying effect of the sigma-1 receptor
agonist on the D1 receptor agonist-induced PKA activation. The PKA
activity was enhanced by 37.2±18.1% (n=4, Pb0.05) at 4 min after
SKF38393 (10 μM) alone, but after the synaptosomes were pretreated
with PDBu (1 μM) for 2 min, the PKA activity induced by SKF38393
was increased by 52.9±22.3% (n=4, Pb0.05, compared to the
SKF38393 alone group).
To explore which isozymes of PKC were responsible for the
amplifying effect of the sigma-1 receptor agonist on the D1 receptor
agonist-induced PKA activation, we observed the inﬂuence of the
selective PKC isozyme inhibitors on the effect of PRE084. We ﬁrst
observed the inﬂuence of rottlerin, a PKC inhibitor that was selective
for the conventional PKC (cPKC) (including α, βI, βII and γ subtypes)
at 30-42 μM [29], on the effect of PRE084. As shown in Fig. 3B, in the
presence of rottlerin (40 μM), the amplifying effect of PRE084 on the
SKF38393-evoked PKA activation disappeared. Rottlerin alone had no
effects on the PKA activity (n=4, PN0.05). Next, we examined the
inﬂuence of the cPKCβ-speciﬁc inhibitor CG53353 (the IC50 value for
cPKCβ, including cPKCβI and cPKCβII, is 3.8 μM and the IC50 value for
cPKCβII is 0.41 μM) [30] on the effect of PRE084. First, we used 4 μM
CGP53353 to inhibit both cPKCβI and cPKCβII. The result showed that
in the presence of 4 μM CGP53353, the amplifying effect of PRE084 on
Fig. 1. Effect of the sigma-1 receptor agonists on the PKA activity and the D1 receptor agonist-induced PKA activation in the synaptosomes from the prelimbic cortex. A: The effect of
the sigma-1 receptor agonist PRE084 (10 μM) on the PKA activity and the D1 receptor agonist SKF38393-induced PKA activation. In the SKF38393 alone group, SKF38393 (10 μM)
was applied at 4 min before the measurement of PKA activity. In the PRE084 alone group, PRE084 (10 μM) was applied at 6 min before the measurement of PKA activity. In the
PRE084+SKF38393 group, the synaptosomes were pretreated with PRE084 for 2 min before SKF38393 and then SKF38393 was applied at 4 min before the measurement of PKA
activity. Top ﬁgure: representative gel electrophoresis; Bottom ﬁgure: the averaged results in a group of animals. *Pb0.05, compared to control; #Pb0.05, compared to the SKF38393
alone group. n=5. B: The effect of the sigma-1 receptor agonist SKF10047 on the PKA activity and the D1 receptor agonist SKF38393-induced PKA activation. In the SKF38393 alone
group, SKF38393 (10 μM) was applied at 4 min before the measurement of PKA activity. In the SKF10047 alone group, SKF10047 (10 μM) was applied at 6 min before the
measurement of PKA activity. In the SKF10047+SKF38393 group, the synaptosomes were pretreated with SKF10047 for 2 min before SKF38393 and then SKF38393 was applied at
4 min before the measurement of PKA activity. Top ﬁgure: representative gel electrophoresis; Bottom ﬁgure: the averaged results in a group of animals. *Pb0.05, compared to
control; #Pb0.05, compared to the SKF38393 alone group. n=4. C: The inﬂuence of the sigma-1 receptor antagonist BMY14802 on the effect of PRE084. In the SKF38393 alone
group, SKF38393 (10 μM) was applied at 4 min before the measurement of PKA activity. In the PRE084+SKF38393 group, synaptosomes were treated by two-phase application of
2 min PRE084 (10 μM) and 4 min SKF38393 in sequence. In the BMY14802+PRE084+SKF38393 group, synaptosomes were treated with three-phase application of 2 min
BMY14802 (25 μM), 2 min PRE084 and 4 min SKF38393 in sequence. *Pb0.05, compared to control; #Pb0.05, compared to the SKF38393 alone group or the PRE084+SKF38393
group. n=4. D: The expression of the sigma-1 receptors in the synaptosomes from the prelimbic cortex and the kidney tissues in Western blotting.
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CGP53353 (4 μM) alone had no effects on the PKA activity (n=4,
PN0.05). However, when we used 0.5 μM CGP53353, which was
selective for cPKCβII, we did not ﬁnd a signiﬁcant inﬂuence of 0.5 μMCGP53353 on the amplifying effect of PRE084 (Fig. 3D, n=4).
CGP53353 (0.5 μM) alone had no effects on the PKA activity (n=4,
PN0.05). We also checked the effect of PRE084 on the activity of
cPKCβI with Western blot analysis. cPKCβI translocation from the
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the relative amount of activated (membrane-bound) cPKCβI, an assay
that was described previously [31]. cPKCβI activation is associatedwith translocation of the protein from the cytosol to cellular mem-
branes. Fig. 4A showed representative immunoblots of the cPKCβI in
both cytosolic and membrane fractions of synaptosomes before and
10 min after addition of PRE084 (10 μM) and the PKC activator PDBu
(1 μM). Calculation of the percentage of cPKCβI in the membrane
fraction revealed that PRE084 increased membrane-bound cPKCβI by
16.4% (Fig. 4B, n=7, Pb0.05), indicating that PRE084 stimulated the
cPKCβI translocation. PDBuhad a similar effect to that of PRE084on the
cPKCβI translocation (Fig. 4, n=7, Pb0.05).
3.3. Intrasynaptosomal Ca2+ plays an important role in the amplifying
effect of the sigma-1 receptor agonist on the D1 receptor agonist-induced
PKA activation
We observed the inﬂuence of the removal of extracellular Ca2+ by
the Ca2+-free medium containing EGTA [32] on the amplifying effect
of the sigma-1 receptor agonist on the D1 receptor agonist-induced
PKA activation. The result showed that the Ca2+-free medium
containing EGTA (1 mM) alone had no effects on the PKA activity
(n=4), but it could abolish the amplifying effect of PRE084 on the
SKF38393-induced PKA activation (Fig. 5A, n=4).
We also examined the inﬂuence of the voltage-gated Ca2+ channel
blocker cadmium [33] on the amplifying effect of the sigma-1 receptor
agonist. The result showed that cadmium (100 μM) alone had no
effects (n=4), but in the presence of cadmium, the amplifying effect
of PRE084 disappeared (Fig. 5B, n=4). To determine whether L-type
Ca2+ channels were involved in the amplifying effect of PRE084, we
observed the inﬂuence of the L-type Ca2+ channel blocker nimodipine
[34] on the effect of PRE084. The results showed that nimodipine
(10 μM) alone had no effects on the PKA activity (n=4, PN0.05), but
it could signiﬁcantly inhibit the amplifying effect of PRE084 on the
SKF38393-evoked PKA activation (n=4, Fig. 5C).
3.4. Activation of PKC by sigma-1 receptor agonists is the upstream event
of the increase in the intrasynaptosomal Ca2+ concentration
To study the relationship between the activation of PKC and the
increase in the intrasynaptosomal Ca2+ concentration in the ampli-
fying effect of the sigma-1 receptor agonist on the D1 receptor
agonist-induced PKA activation, we observed the inﬂuence of the PKC
inhibitor chelerythrine on the sigma-1 agonist-induced increase in
the intrasynaptosomal Ca2+ concentration. The result showed that in
the presence of chelerythrine, the effect of PRE084 on the intrasy-
naptosomal Ca2+ concentration disappeared (Fig. 6A). The averaged
increase percentage of the Ca2+ concentration after PRE084 (10 μM)
alone was 24.2±1.7% (n=6, Pb0.05, compared to control), but in theFig. 2. Inﬂuence of the sigma-1 receptor agonist on the cAMP- and the AC activator-
induced PKA activation and the effect of the sigma-1 receptor agonist on the D1
receptor agonist-induced AC activation in the synaptosomes from the prelimbic cortex.
A: The inﬂuence of the sigma-1 receptor agonist PRE084 on the membrane-permeable
analog of cAMP (CPT-cAMP)-induced PKA activation. In the cAMP alone group, cAMP
(1 μM) was applied at 4 min before the measurement of PKA activity. In the PRE084
alone group, PRE084 (10 μM) was applied at 6 min before the measurement of PKA
activity. In the PRE084+cAMP group, synaptosomes were treated by two-phase
application of 2 min PRE084 and 4 min cAMP in sequence. *Pb0.05, compared to
control; #Pb0.05, compared to the CPT-cAMP alone group. n=4. B: The inﬂuence of
the sigma-1 receptor agonist PRE084 on the AC activator forskolin -induced PKA
activation. In the forskolin alone group, forskolin (20 μM) was applied at 4 min before
the measurement of PKA activity. In the PRE084 alone group, PRE084 (10 μM) was
applied at 6 min before the measurement of PKA activity. In the PRE084+forskolin
group, synaptosomes were treated by two-phase application of 2 min PRE084 and
4 min forskolin in sequence. *Pb0.05, compared to control; #Pb0.05, compared to the
forskolin alone group. n=4. C: The effect of the sigma-1 receptor agonist PRE084 on the
D1 receptor agonist SKF38393-induced AC activation. In the SKF38393 alone group,
SKF38393 (10 μM) was applied at 4 min before the measurement of AC activity. In the
PRE084 alone group, PRE084 (10 μM) was applied at 6 min before the measurement of
AC activity. In the PRE084+SKF38393 group, synaptosomes were treated by two-
phase application of 2 min PRE084 and 4 min SKF38393 in sequence. *Pb0.05,
compared to control. n=8.
Fig. 3. Inﬂuence of PKC inhibitors on the amplifying effect of the sigma-1 receptor agonist on the D1 receptor agonist-induced PKA activation in the synaptosomes from the prelimbic
cortex. A: Inﬂuence of the wide-spectrum PKC inhibitor chelerythrine on the amplifying effect of the sigma-1 receptor agonist PRE084. In the SKF38393 alone group, SKF38393
(10 μM) was applied at 4 min before the measurement of PKA activity. In the PRE084+SKF38393 group, synaptosomes were treated by two-phase application of 2 min PRE084
(10 μM) and 4 min SKF38393 in sequence. In the chelerythrine+PRE084+SKF38393 group, synaptosomes were treated with three-phase application of 2 min chelerythrine
(2.5 μM), 2 min PRE084 and 4 min SKF38393 in sequence. *Pb0.05, compared to control; #Pb0.05, compared to the SKF38393 alone group or the PRE084+SKF38393 group. n=4.
B: Inﬂuence of the cPKC inhibitor rottlerin on the amplifying effect of the sigma-1 receptor agonist PRE084. In the SKF38393 alone group, SKF38393 (10 μM) was applied at 4 min
before the measurement of PKA activity. In the PRE084+SKF38393 group, synaptosomes were treated by two-phase application of 2 min PRE084 (10 μM) and 4 min SKF38393 in
sequence. In the rottlerin+PRE084+SKF38393 group, synaptosomes were treated with three-phase application of 2 min rottlerin (40 μM), 2 min PRE084 and 4 min SKF38393 in
sequence. *Pb0.05, compared to control; #Pb0.05, compared to the SKF38393 alone group or the PRE084+SKF38393 group. n=4. C: Inﬂuence of the cPKCβ inhibitor CGP53353 on
the amplifying effect of the sigma-1 receptor agonist PRE084. In the SKF38393 alone group, SKF38393 (10 μM) was applied at 4 min before the measurement of PKA activity. In the
PRE084+SKF38393 group, synaptosomes were treated by two-phase application of 2 min PRE084 (10 μM) and 4 min SKF38393 in sequence. In the CGP53353+PRE084+
SKF38393 group, synaptosomes were treated with three-phase application of 2 min CGP53353 (4 μM), 2 min PRE084 and 4 min SKF38393 in sequence. *Pb0.05, compared to
control; #Pb0.05, compared to the SKF38393 alone group or the PRE084+SKF38393 group. n=4. D: Inﬂuence of the cPKCβII inhibitor CGP53353 (0.5 μM) on the amplifying effect
of the sigma-1 receptor agonist PRE084. In the SKF38393 alone group, SKF38393 (10 μM) was applied at 4 min before the measurement of PKA activity. In the PRE084+SKF38393
group, synaptosomes were treated by two-phase application of 2 min PRE084 (10 μM) and 4 min SKF38393 in sequence. In the CGP53353+PRE084+SKF38393 group,
synaptosomes were treated with three-phase application of 2 min CGP53353 (0.5 μM), 2 min PRE084 and 4 min SKF38393 in sequence. *Pb0.05, compared to control; #Pb0.05,
compared to the SKF38393 alone group or the PRE084+SKF38393 group. n=4.
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4.1±1.5 % (n=6, PN0.05, compared to control). Moreover, being
consistent with the results of the above PKC isozyme experiments
involving the mechanism of the amplifying effect of the sigma-1
receptor agonist on the D1 receptor agonist-induced PKA activation,
both the cPKC inhibitor rottlerin (Fig. 6B, n=6) and the cPKCβinhibitor CG53353 (4 μM) (Fig. 6C, n=6) could also block the effect of
PRE084 on the intrasynaptosomal Ca2+ concentration. In addition, the
L-type Ca2+ channel blockers nimodipine (Fig. 7A, n=6) and
verapamil [35] (Fig. 7B, n=6) could also abolish the effect of
PRE084 on the intrasynaptosomal Ca2+ concentration. However, we
did not ﬁnd a signiﬁcant inﬂuence of the N-type Ca2+ channel blocker
Fig. 4. Effect of PRE084 on the activity of cPKCβI using Western blot analysis in the
synaptosomes from the prelimbic cortex. cPKCβI translocation from the cytosolic to
membrane fraction in synaptosomes was used to assess the relative amount of
activated (membrane-bound) cPKCβI. A: Representative immunoblots of the cPKCβI in
both cytosolic and membrane fractions of synaptosomes before and 10 min after
addition of PRE084 (10 μM) and PDBu (1 μM). B: Calculation of the percentage of
cPKCβI in the membrane fraction before and 10 min after addition of PRE084 (10 μM)
and PDBu (1 μM). *Pb0.05, compared to control. n=7.
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channel blocker ω-agatoxin IVA [37] (Fig. 7D, n=6) on the effect of
PRE084 on the intrasynaptosomal Ca2+ concentration. We also did
not ﬁnd a signiﬁcant inﬂuence of the NMDA receptor antagonistFig. 5. Inﬂuence of the extracellular Ca2+ chelator, the voltage-gated Ca2+ channel
blocker and the L-type Ca2+ channel blocker on the amplifying effect of the sigma-1
receptor agonist on the D1 receptor agonist-induced PKA activation in the synapto-
somes from the prelimbic cortex. A: Inﬂuence of the removal of the extracellular Ca2+
by the Ca2+-free medium containing EGTA on the amplifying effect of the sigma-1
receptor agonist PRE084. In the SKF38393 alone group, SKF38393 (10 μM) was applied
at 4 min before the measurement of PKA activity. In the PRE084+SKF38393 group,
synaptosomes were treated by two-phase application of 2 min PRE084 (10 μM) and
4 min SKF38393 in sequence. In the Ca2+-free medium containing EGTA+PRE084+
SKF38393 group, synaptosomes were treated with three-phase application of 2 min
Ca2+-free medium containing EGTA (1 mM), 2 min PRE084 and 4 min SKF38393 in
sequence. *Pb0.05, compared to control; #Pb0.05, compared to the SKF38393 alone
group or the PRE084+SKF38393 group. n=4. B: Inﬂuence of the voltage-gated Ca2+
channel blocker cadmium on the amplifying effect of the sigma-1 receptor agonist
PRE084. In the SKF38393 alone group, SKF38393 (10 μM) was applied at 4 min before
the measurement of PKA activity. In the PRE084+SKF38393 group, synaptosomes
were treated by two-phase application of 2 min PRE084 (10 μM) and 4 min SKF38393
in sequence. In the cadmium+PRE084+SKF38393 group, synaptosomes were treated
with three-phase application of 2 min cadmium (100 μM), 2 min PRE084 and 4 min
SKF38393 in sequence. *Pb0.05, compared to control; #Pb0.05, compared to the
SKF38393 alone group or the PRE084+SKF38393 group. n=4. C: Inﬂuence of the L-
type Ca2+ channel blocker nimodipine on the amplifying effect of the sigma-1 receptor
agonist PRE084. In the SKF38393 alone group, SKF38393 (10 μM) was applied at 4 min
before the measurement of PKA activity. In the PRE084+SKF38393 group, synapto-
somes were treated by two-phase application of 2 min PRE084 (10 μM) and 4 min
SKF38393 in sequence. In the nimodipine+PRE084+SKF38393 group, synaptosomes
were treated with three-phase application of 2 min nimodipine (10 μM), 2 min PRE084
and 4 min SKF38393 in sequence. *Pb0.05, compared to control; #Pb0.05, compared to
the SKF38393 alone group or the PRE084+SKF38393 group. n=4.
Fig. 6. Inﬂuence of PKC inhibitors on the effect of the sigma-1 receptor agonist on the intrasynaptosomal Ca2+ concentration in the synaptosomes from the prelimbic cortex.
A: Inﬂuence of the wide-spectrum PKC inhibitor chelerythrine on the effect of the sigma-1 receptor agonist PRE084 on the intrasynaptosomal Ca2+ concentration. In the PRE084
alone group, PRE084 (10 μM) was applied at 4 min before the measurement of Ca2+ concentration. In the chelerythrine+PRE084 group, synaptosomes were treated by two-phase
application of 2 min chelerythrine (2.5 μM) and 4 min PRE084 in sequence. *Pb0.05, compared to control; #Pb0.05, compared to the PRE084 alone group. n=6. B: Inﬂuence of the
cPKC inhibitor rottlerin on the effect of the sigma-1 receptor agonist PRE084 on the intrasynaptosomal Ca2+ concentration. In the PRE084 alone group, PRE084 (10 μM) was applied
at 4 min before the measurement of Ca2+ concentration. In the rottlerin+PRE084 group, synaptosomes were treated by two-phase application of 2 min rottlerin (40 μM) and 4 min
PRE084 in sequence. *Pb0.05, compared to control; #Pb0.05, compared to the PRE084 alone group. n=6. C: Inﬂuence of the cPKCβ inhibitor CGP53353 (4 μM) on the effect of the
sigma-1 receptor agonist PRE084 on the intrasynaptosomal Ca2+ concentration. In the PRE084 alone group, PRE084 (10 μM) was applied at 4 min before the measurement of Ca2+
concentration. In the CGP53353+PRE084 group, synaptosomes were treated by two-phase application of 2 min CGP53353 (4 μM) and 4 min PRE084 in sequence. *Pb0.05,
compared to control; #Pb0.05, compared to the PRE084 alone group. n=6.
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concentration (Fig. 7E, n=6). In addition, we also checked the role of
intracellular Ca2+ stores in the sigma-1 receptor-mediated intrasy-
naptosomal Ca2+ increase. The result showed that thapsigargin,
which depleted all intracellular Ca2+ stores by inhibiting the
endosomal Ca2+-ATPase activity [39], had no signiﬁcant inﬂuence
on the effect of PRE084. PRE084 (10 μM) still increased the intra-
synaptosomal Ca2+ concentration by 22.6±3.8% (n=6, Pb0.05) in
the presence of thapsigargin (25 μM), showing no signiﬁcantdifference from that (22.9±3.8%, n=6) of the PRE084 alone group
(PN0.05).4. Discussion
One of the main ﬁndings of the present study is that sigma-1
receptor agonists can amplify the D1 receptor agonist-induced PKA
activation at presynaptic sites in the prelimbic cortex. To the best of
Fig. 7. Inﬂuence of the L-type Ca2+ channel blockers, the N-type Ca2+ channel blocker, the P/Q-type Ca2+ channel blocker and the NMDA receptor antagonist on the effect of the
sigma-1 receptor agonist on the intrasynaptosomal Ca2+ concentration in the synaptosomes from the prelimbic cortex. A: The inﬂuence of the L-type Ca2+ channel blocker
nimodipine on the effect of the sigma-1 receptor agonist PRE084 on the intrasynaptosomal Ca2+ concentration. In the PRE084 alone group, PRE084 (10 μM) was applied at 4 min
before the measurement of Ca2+ concentration. In the nimodipine+PRE084 group, synaptosomes were treated by two-phase application of 2 min nimodipine (10 μM) and 4 min
PRE084 in sequence. *Pb0.05, compared to control; #Pb0.05, compared to the PRE084 alone group. n=6. B: The inﬂuence of the L-type Ca2+ channel blocker verapamil on the effect
of the sigma-1 receptor agonist PRE084 on the intrasynaptosomal Ca2+ concentration. In the PRE084 alone group, PRE084 (10 μM) was applied at 4 min before the measurement of
Ca2+ concentration. In the verapamil+PRE084 group, synaptosomes were treated by two-phase application of 2 min verapamil (50 μM) and 4 min PRE084 in sequence. *Pb0.05,
compared to control; #Pb0.05, compared to the PRE084 alone group. n=6. C: The inﬂuence of the N-type Ca2+ channel blocker ω-contotoxin GVIA on the effect of the sigma-1
receptor agonist PRE084 on the intrasynaptosomal Ca2+ concentration. In the PRE084 alone group, PRE084 (10 μM) was applied at 4 min before the measurement of Ca2+
concentration. In the ω-contotoxin GVIA+PRE084 group, synaptosomes were treated by two-phase application of 2 min ω-contotoxin GVIA (0.5 μM) and 4 min PRE084 in
sequence. *Pb0.05, compared to control. n=6. D: The inﬂuence of the P/Q-type Ca2+ channel blocker ω-agatoxin IVA on the effect of the sigma-1 receptor agonist PRE084 on the
intrasynaptosomal Ca2+ concentration. In the PRE084 alone group, PRE084 (10 μM) was applied at 4 min before the measurement of Ca2+ concentration. In the ω-agatoxin IVA+
PRE084 group, synaptosomes were treated by two-phase application of 2 min ω-agatoxin IVA (0.5 μM) and 4 min PRE084 in sequence. *Pb0.05, compared to control. n=6. E: The
inﬂuence of the NMDA receptor antagonist MK801 on the effect of the sigma-1 receptor agonist PRE084 on the intrasynaptosomal Ca2+ concentration. In the PRE084 alone group,
PRE084 (10 μM)was applied at 4 min before the measurement of Ca2+ concentration. In the MK801+PRE084 group, synaptosomes were treated by two-phase application of 2 min
MK801 (20 μM) and 4 min PRE084 in sequence. *Pb0.05, compared to control. n=6.
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receptor signaling by sigma-1 receptors.
The concentration (10 μM) of PRE084 used here to produce the
effect was larger than the Ki value (44 nM) of PRE084 [40], but this
effect should be speciﬁc to the sigma-1 receptors. The evidence
supporting this statement was that (1) the speciﬁc sigma-1 receptor
antagonist BMY14802 could completely abolish the effect of PRE084;
(2) in the literature, although the Ki value of PRE084 for the sigma-1
receptors was in the nanomolar range, the IC50 values of PRE084 for
producing effects via the activation of the sigma-1 receptors were
generally in the micromoles range. For example, the IC50 value of
PRE084 for the inhibition of the ASIC1a-induced [Ca2+]i increase was
13.7 μM [41] and for the protection of human retinal cells against
oxidative stress was 10 μM [42].Sigma-1 receptors have been known to exist at postsynaptic sites.
In addition, a number of evidence suggested that sigma-1 receptors
might also exist at presynaptic sites. The evidence supporting the
existence of sigma-1 receptors at presynaptic sites was that (1) the
functional experiments in brain slices [43–45] and synaptosomes (a
preparation of presynaptic terminals) [46] showed that the activation
of sigma-1 receptors could modulate presynaptic neurotransmitter
release; (2) radioligand binding experiments showed that selective
sigma-1 receptor agonists could bind with synaptosomes with high
afﬁnity in a competitive manner [47]. Moreover, the present study
showed the existence of sigma-1 receptors in the synaptosomes by
Western blotting.
The signaling pathway between D1 receptors and PKA involves the
coupling to Gs-protein, the activation of AC and the action of cAMP on
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receptors in this pathway. First, we used CPT-cAMP, a membrane-
permeable analog of cAMP, to generate the cAMP-induced PKA
activation and then observed the inﬂuence of the sigma-1 receptor
agonist on this activation. The result showed that the sigma-1
receptor agonist could potentiate the effect of CPT-cAMP on PKA.
Then, we used forskolin, an activator of AC, to generate the AC/cAMP-
induced PKA activation and observed the inﬂuence of the sigma-1
receptor agonist on this activation. The result showed that the sigma-
1 receptor agonist could also potentiate this activation. However, we
did not ﬁnd that the sigma-1 receptor agonist had the potentiating
effect on the D1 receptor agonist-induced AC activation. These results
suggest that the sigma-1 receptor agonist may amplify D1 receptor
signaling via amplifying the action of cAMP on PKA.
It has been known that the downstream pathway of the sigma-1
receptors involves the activation of PKC and the enhancement of
intracellular Ca2+ concentration. Therefore, it is possible that PKC and
intracellular Ca2+, as important downstream signaling molecules of
sigma-1 receptors, play an important role in the amplifying effect of the
sigma-1 receptor agonist on the D1 receptor agonist-induced PKA
activation. This hypothesis has been conﬁrmedby our results.Moreover,
this result provides evidence supporting that sigma-1 receptors may
amplify D1 receptor signaling via PKC and intracellular Ca2+.
Noteworthily,whenwe removed theextracellular Ca2+by the Ca2+-
free medium containing EGTA, the activity of PKA returned to the
control levels but cadmium and nimodipine only inhibited the
amplifying effect achieved by PRE084. This phenomenon suggests
possible involvement of another Ca2+ source in the D1 receptor-
inducedPKAactivation. In this aspect, it's possible that this another Ca2+
source may be from D-1 receptor-induced intracellular Ca2+ release
because it is shown that the activation of D1 receptors can result in a rise
in intracellular Ca2+ through both extracellular inﬂux and release from
intracellular compartments [48].
PKC family includes at least 12 isozymes, which are classiﬁed into
three major groups [49]. The ﬁrst of these groups is the conventional
PKC (cPKC), which includes α, βI, βII and γ types. The second group,
called the novel PKC (nPKC), includes δ, ε, η and θ type. The third
group is the atypical PKC (aPKC), including ζ and λ type. The PKC
isozymes are distributed in various tissues. Among them, cPKC is the
one localized at presynaptic terminals [50]. So it is possible that cPKC
plays an important role in the amplifying effect of the sigma-1
receptor agonist on the D1 receptor agonist-induced PKA activation.
This hypothesis was conﬁrmed by our result that the cPKC selective
inhibitor rottlerin could abolish the effect of the sigma-1 receptor
agonist. Moreover, CG53353 at 4 μM, which inhibited both PKCβII and
PKCβI of cPKC, could also abolish the effect of the sigma-1 receptor
agonist. However, CGP53353 at 0.5 μM, which was selective for
PKCβII, had no inﬂuence. These results suggest that the cPKC,
especially the PKCβI, may play a key role in the effect of the
amplifying effect of the sigma-1 receptor agonist on the D1 receptor
agonist-induced PKA activation.
About the source of Ca2+ involving the amplifying effect of the
sigma-1 receptor agonist on the D1 receptor agonist-induced PKA
activation, it may involve the promotion of the extracellular Ca2+
inﬂux or the mobilization of the intracellular Ca2+ store. In the
present paper, we studied the role of the extracellular Ca2+ in the
effect of the sigma-1 receptor agonist. The result showed that after
removing the extracellular Ca2+ by the Ca2+-free medium containing
EGTA, the amplifying effect of the sigma-1 receptor agonist dis-
appeared. Moreover, the voltage-gated Ca2+ channel blocker cadmi-
um and the L-type Ca2+ channel blocker nimodipine could abolish the
amplifying effect of the sigma-1 receptor agonist, suggesting that the
extracellular Ca2+ inﬂux through the L-type Ca2+ channels might
mediate the amplifying effect of the sigma-1 receptor agonist.
About the relationship between the activation of PKC and the
increase in the intrasynaptosomal Ca2+ concentration in the ampli-fying effect of the sigma-1 receptor agonist on theD1 receptor agonist-
induced PKA activation, our results suggested that the activation of
PKC by sigma-1 receptor agonists might be the upstream event of the
increase in the intrasynaptosomal Ca2+ concentration. Interestingly,
based on our results, it appeared that the sigma-1 receptors could
modulate the resting-state L-type Ca2+ channels, which then led to an
increase in the intrasynaptosomal Ca2+ concentration. This statement
was consistent with the evidence: (1) there were spontaneous L-type
Ca2+ channel activities at the rest membrane potentials [51] and these
activities contributed to the genesis of spontaneous Ca2+ sparks in the
cytoplasm [52]; (2) some active substances, such as ganglioside and
phorbol ester (the PKC activator), could increase the Ca2+ inﬂux
through the modulation of these activities [53,54]. However, how
sigma-1 receptors modulate the resting-state L-type Ca2+ channels
remains to be studied. In addition, previous studies in NG-108 and
SHSY5Y cell lines showed that the sigma-1 receptor agonists enhanced
the intracellular Ca2+ by the mobilization of the intracellular Ca2+
store [55–57]. However, this mechanism might not be involved in the
effect of the sigma-1 receptor agonists on the intrasynaptosomal Ca2+
concentration in the prelimbic cortex because our result showed that
the intracellular Ca2+ store depleter hadno signiﬁcant inﬂuence on the
effect of the sigma-1 receptor agonist. Moreover, the present result
that the removal of the extracellular Ca2+ by the Ca2+-free medium
containing EGTA could abolish the effect of the sigma-1 receptor
agonist also supported that themechanism of the effect of the sigma-1
receptor agonist on the intrasynaptosomal Ca2+ concentration might
involve the promotion of the extracellular Ca2+ inﬂux, rather than the
mobilization of the intracellular Ca2+ store.
Subcellular distribution of sigma-1 receptors has been studied
with radioligand binding in subcellular fractions, and more recently
with immunochemical methods. These studies found that sigma-1
receptors were abundant in endoplasmic reticulum (ER), nuclear,
mitochondrial and synaptic membranes (synaptosomes) [3]. Howev-
er, it appears that the functions of sigma-1 receptors in different
subcellular fractions are different. For example, recent studies show
that the sigma-1 receptors in the ER, as a Ca2+-sensitive and ligand-
operated receptor chaperone at mitochondrion-associated ER mem-
brane (MAM), can lead to a prolonged Ca2+ signaling into the
mitochondria via IP3 receptors, and thus regulating ER-mitochondrial
interorganellar Ca2+ signaling and cell survival [58]; the present study
shows that one function of the sigma-1 receptors at presynaptic sites
(synaptosomes) may amplify the D1 receptor agonist-induced PKA
activation by the sigma-1 receptors-cPKC (especially the PKCβI)- L-
type Ca2+ channels-Ca2+-AC and/or cAMP signaling pathway (Fig. 8).
It is noteworthy that the synaptosomal preparation may be
contaminated with ER or mitochondrion where sigma-1 receptors
are highly concentrated in a specialized area known as the MAM. But
this contamination may not contribute to the amplifying effect of the
sigma-1 receptor agonist on the D1 receptor agonist-induced PKA
activation because these contaminated ER or mitochondria are in the
extrasynaptosomal space.
Signiﬁcance – It has been known that the dopaminergic projection
from the ventral tegmental area to the prelimbic cortex plays a major
role in cognition and neuropsychiatric processes. In particular, the
involvement of prefrontal D1 dopamine receptors in the behavioral
sensitization to psychostimulants has received much attention. The
activation of D1 receptors in the prelimbic cortex stimulated
psychostimulant-induced motor activity and increased behavioral
sensitization to psychostimulants [59–62]. Thus, the present ﬁnding
that the sigma-1 receptors can amplify the presynaptic dopamine D1
receptor signaling in the prelimbic cortex is of signiﬁcance for
understanding the neuronal basis of the behavioral sensitization
induced by sigma-1 receptors. In addition, the present ﬁnding that
the activation of sigma-1 receptors ampliﬁes the D1 receptor-induced
PKA activation via cPKC (especially the PKCβI) - L-type Ca2+ channels -
Ca2+ - AC and/or cAMP signaling pathway is of important signiﬁcance
Fig. 8. Schematic representation of the possible mechanism underlying the amplifying
effect of the sigma-1 receptor agonist on theD1 receptor agonist-induced PKA activation
in the synaptosomes from the prelimbic cortex. The sigma-1 receptor in the presynaptic
site may amplify the D1 receptor agonist-induced PKA activation by sigma-1 receptors -
cPKC (especially the PKCβI) - L-type Ca2+ channels - Ca2+ - AC and/or cAMP signaling
pathway.
1407Y. Fu et al. / Biochimica et Biophysica Acta 1803 (2010) 1396–1408for revealing the downstream signal transduction pathway of sigma-1
receptors.
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